Insider Trading June 18, 2026 06:40 PM

HRT Financial LP Liquidates Remaining Aditxt Holdings Following Significant Share Divestment

Insider divestment coincides with broader corporate restructuring and financial maneuvers by Aditxt Inc.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ADTX

HRT Financial LP, previously a substantial ten percent shareholder in Aditxt Inc., has fully exited its position in the company. The firm sold its remaining 3,132,480 Class A shares on June 16, 2026, for a total transaction value of $40,722. This complete liquidation occurs against a backdrop of severe stock depreciation and significant corporate restructuring at Aditxt, including a pending reverse stock split and the separation of its subsidiary, Ignite Proteomics.

HRT Financial LP Liquidates Remaining Aditxt Holdings Following Significant Share Divestment
ADTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • HRT Financial LP has fully liquidated its 3,132,480 share position in Aditxt for $40,722, ending its status as a ten percent owner.
  • Aditxt is executing a 1-for-27 reverse stock split and raising $1.25 million through senior unsecured promissory notes to stabilize its financial position.
  • Subsidiary Ignite Proteomics is set to go public via a SPAC deal valued at $150 million, with Jeffrey M. Busch appointed as interim CEO of the parent company.

HRT Financial LP has executed a complete exit from its position in Aditxt Inc. (ADTX), marking the end of its tenure as a significant shareholder in the micro-cap entity. The firm, which previously held a ten percent stake in the company, disposed of its remaining 3,132,480 Class A shares on June 16, 2026. The transaction resulted in a total proceeds value of $40,722, with the shares changing hands at a price of $0.013 per unit. Following this divestment, HRT Financial LP no longer retains any Class A equity holdings in Aditxt.

The timing of this liquidation is notable given the precarious market performance of the underlying asset. Aditxt shares have experienced a severe decline, dropping 23% over the preceding week and nearly 100% year-to-date as of the transaction date. At the time of the sale, the stock was trading at $0.01. Data from InvestingPro indicates that the company's market capitalization has contracted to a mere $10,000. Furthermore, the company carries a financial health score of 0.86, categorized as "WEAK." This transaction was formally reported to the Securities and Exchange Commission on June 18, 2026.

Concurrently, Aditxt is undergoing substantial structural and financial reorganization. The company recently announced that its subsidiary, Ignite Proteomics, will transition to a public entity through a special purpose acquisition company (SPAC) transaction. This move is valued at approximately $150 million for Ignite and will result in the creation of Ignite Proteomics Inc., an independent publicly traded company. To manage the transition, Aditxt has appointed Jeffrey M. Busch as interim CEO. Busch will continue his existing role as CEO of Ignite Proteomics while assuming leadership of the parent company.

On the financial front, Aditxt is implementing a 1-for-27 reverse stock split of its common stock, effective May 18, 2026. To bolster its capital structure, the company has also disclosed a $1.25 million private placement of senior unsecured promissory notes. These notes carry an annual interest rate of 10% and are scheduled to mature on September 30, 2026. Additionally, Aditxt has regained compliance with Nasdaq’s continued listing standards. This compliance was confirmed via a letter from The Nasdaq Stock Market LLC, following the company's report of stockholders’ equity of $3,953,682 in its Annual Report.

The market data reflects significant volatility. ADTX closed at $0.0103, representing a gain of $0.0059 or 134.09% for the day. In after-hours trading, the stock traded at $0.0116, up $0.0016 or 16.00%. These fluctuations highlight the extreme sensitivity of the asset to corporate announcements and liquidity events.

Risks

  • Aditxt faces severe valuation challenges, with a market capitalization of only $10,000 and a financial health score of 0.86, indicating potential solvency or operational difficulties.
  • The stock has declined nearly 100% year-to-date, suggesting high volatility and potential liquidity risks for remaining shareholders in the micro-cap sector.

More from Insider Trading

Vistra Director Executes $4 Million Share Sale Under Pre-Arranged Plan Jun 18, 2026 General Motors CEO Mary Barra Executes Stock Transactions Amid Strategic Expansion Jun 18, 2026 Venture Global CFO Offloads $2.44M in Stock Amid Strategic Expansion Jun 18, 2026 Nektar Therapeutics CEO Executes $1.2M Stock Sale Under Pre-Arranged Plan Jun 18, 2026 Hut 8 Corp. Chief Legal Officer Executes $1.25M Stock Sale Amid Expansion and Leadership Transition Jun 18, 2026